Please select the option that best describes you:
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
Would you consider using Enhertu based on the Destiny-Gastric03 data?
Would you consider using Enhertu based on the Destiny-Gastric03 data?